|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2400091288 |
|
最近更新日期: Date of Last Refreshed on: |
2024-10-24 16:42:24 |
|
注册时间: Date of Registration: |
2024-10-24 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
基于机器学习的维持性血液透析患者自体动静脉内瘘血管狭窄风险因素的构建 |
|
Public title: |
Construction of risk factors for vascular stenosis of autologous arteriovenous fistula in maintenance hemodialysis patients based on machine learning |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
维持性血液透析患者自体动静脉内瘘血管狭窄风险预测模型的构建 |
|
Scientific title: |
Construction of risk factors for vascular stenosis of autologous arteriovenous fistula in maintenance hemodialysis patients based on machine learning |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
杨芳 |
研究负责人: |
柏晓玲 |
|
Applicant: |
yangfang |
Study leader: |
Bai Xiaoling |
|
申请注册联系人电话: Applicant telephone: |
+86 182 8502 7347 |
研究负责人电话:
Study leader's |
+86 854 541 2910 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
782039419@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
baixiaoling2003@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
贵州省贵阳市云岩区文昌北路 |
研究负责人通讯地址: |
贵州省黔南布依族苗族自治州贵定县盘江镇 |
|
Applicant address: |
Wenchang North Road, Yunyan District, Guiyang City, Guizhou Province |
Study leader's address: |
Panjiang Town, Guding County, Qiannan Buyi and Miao Autonomous Prefecture, Guizhou Province |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
贵州中医药大学 |
||
|
Applicant's institution: |
Guizhou University of Traditional Chinese Medicine |
||
|
研究负责人所在单位: |
贵州护理职业技术学院;贵州省人民医院 |
||
|
Affiliation of the Leader: |
Guizhou Nursing Vocational college;Guizhou Provincial People's Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2024-078 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
贵州省人民医院 |
||
|
Name of the ethic committee: |
Guizhou Provincial People's Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-06-07 00:00:00 | ||
|
伦理委员会联系人: |
贵州省人民医院伦理办 |
||
|
Contact Name of the ethic committee: |
Ethics Office of Guizhou Provincial People's Hospital |
||
|
伦理委员会联系地址: |
贵州省贵阳市中山东路83号 |
||
|
Contact Address of the ethic committee: |
83 Zhongshan East Road, Guiyang City, Guizhou Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 851 8560 0570 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
贵州护理职业技术学院;贵州省人民医院 |
||||||||||||||||||||||||||||||||||||||||||||
|
Primary sponsor: |
Guizhou Nursing Vocational college;Guizhou Provincial People's Hospital |
||||||||||||||||||||||||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
贵州省黔南布依族苗族自治州贵定县盘江镇 |
||||||||||||||||||||||||||||||||||||||||||||
|
Primary sponsor's address: |
Panjiang Town, Guding County, Qiannan Buyi and Miao Autonomous Prefecture, Guizhou Province |
||||||||||||||||||||||||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||||||||||||||||||||||||
|
经费或物资来源: |
2023年度贵州护理职业技术学院科研项目基金(gzhlyj2023-02) |
||||||||||||||||||||||||||||||||||||||||||||
|
Source(s) of funding: |
2023 Research Project Fund of Guizhou Nursing Vocational and Technical College (gzhlyj2023-02) |
||||||||||||||||||||||||||||||||||||||||||||
|
研究疾病: |
血液透析患者自体动静脉内瘘 |
||||||||||||||||||||||||||||||||||||||||||||
|
Target disease: |
Autologous arteriovenous fistula in hemodialysis patients |
||||||||||||||||||||||||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||||||||||||||||||||||||
|
研究所处阶段: |
I期临床试验 | ||||||||||||||||||||||||||||||||||||||||||||
|
Study phase: |
1 |
||||||||||||||||||||||||||||||||||||||||||||
|
研究设计: |
病例对照研究 |
||||||||||||||||||||||||||||||||||||||||||||
|
Study design: |
Case-Control study |
||||||||||||||||||||||||||||||||||||||||||||
|
研究目的: |
本研究旨在旨在分析MHD患者AVF血管狭窄的危险因素,筛选核心变量,构建MHD患者AVF血管狭窄风险预测模型,为医务人员筛查MHD患者AVF血管狭窄高危人群提供有效评估工具,便于其快速、准确地做出判断,并为制定个性化干预方案提供科学依据。 |
||||||||||||||||||||||||||||||||||||||||||||
|
Objectives of Study: |
The purpose of this study was to analyze the risk factors of AVF vascular stenosis in MHD patients, screen core variables, and build a risk prediction model for AVF vascular stenosis in MHD patients, so as to provide an effective assessment tool for medical personnel to screen high-risk groups of AVF vascular stenosis in MHD patients, facilitate them to make judgments quickly and accurately, and provide a scientific basis for formulating personalized intervention programs. |
||||||||||||||||||||||||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||||||||||||||||||||||||
|
纳入标准: |
①患者年龄≥18岁;②所有以AVF作为血管通路的MHD患者;③在AVF成熟后开始使用时,可提供≥200mL/min血流量;④透析频率为2~3次/周;⑤患者知情同意。 |
||||||||||||||||||||||||||||||||||||||||||||
|
Inclusion criteria |
① Patients ≥18 years old; ② All MHD patients with AVF as vascular access; ③ When AVF is used after maturity, it can provide ≥200mL/min blood flow; The dialysis frequency is 2 ~ 3 times/week; (5) Patient informed consent. |
||||||||||||||||||||||||||||||||||||||||||||
|
排除标准: |
①合并严重并发症,如严重感染、急性心力衰竭等;②参与药物或其他干预研究的患者。 |
||||||||||||||||||||||||||||||||||||||||||||
|
Exclusion criteria: |
① Serious complications, such as severe infection, acute heart failure, etc.; ② Patients participating in drug or other intervention studies. |
||||||||||||||||||||||||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-10-28 00:00:00至 To 2025-06-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2024-10-28 00:00:00 至 To 2025-06-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
2025-06 excel |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
excel 2025 - 06 |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Case sheet |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |